Foster Dykema Cabot & Partners LLC Has $818,000 Stock Holdings in Danaher Co. (NYSE:DHR)

Foster Dykema Cabot & Partners LLC raised its holdings in shares of Danaher Co. (NYSE:DHR) by 30.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 3,561 shares of the conglomerate’s stock after purchasing an additional 836 shares during the quarter. Foster Dykema Cabot & Partners LLC’s holdings in Danaher were worth $818,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in DHR. Kentucky Retirement Systems Insurance Trust Fund lifted its stake in Danaher by 11.6% in the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate’s stock valued at $4,874,000 after buying an additional 2,202 shares during the period. ORG Partners LLC increased its stake in shares of Danaher by 1,212.8% in the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock valued at $636,000 after acquiring an additional 2,559 shares during the last quarter. Generate Investment Management Ltd acquired a new stake in shares of Danaher in the 4th quarter valued at approximately $8,044,000. Compass Capital Management Inc. boosted its stake in Danaher by 4.8% during the 4th quarter. Compass Capital Management Inc. now owns 237,922 shares of the conglomerate’s stock worth $54,615,000 after acquiring an additional 10,994 shares during the last quarter. Finally, Channing Global Advisors LLC grew its holdings in Danaher by 42.8% during the fourth quarter. Channing Global Advisors LLC now owns 5,666 shares of the conglomerate’s stock valued at $1,301,000 after purchasing an additional 1,698 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 11.10% of the company’s stock.

Danaher Trading Up 0.5 %

Danaher stock opened at $190.85 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The firm has a 50-day moving average of $202.61 and a 200-day moving average of $228.47. The company has a market cap of $136.40 billion, a price-to-earnings ratio of 36.15, a P/E/G ratio of 2.66 and a beta of 0.86. Danaher Co. has a one year low of $171.00 and a one year high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the previous year, the firm earned $2.09 earnings per share. On average, equities analysts expect that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.67%. This is an increase from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Friday, March 28th. Danaher’s payout ratio is presently 24.24%.

Analyst Ratings Changes

DHR has been the topic of several analyst reports. Barclays upgraded shares of Danaher from an “equal weight” rating to an “overweight” rating and cut their target price for the stock from $240.00 to $205.00 in a report on Thursday, April 10th. Jefferies Financial Group dropped their price objective on Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. Robert W. Baird set a $231.00 target price on Danaher in a research note on Wednesday. Stifel Nicolaus raised Danaher from a “hold” rating to a “buy” rating and set a $260.00 price target on the stock in a research report on Friday, March 14th. Finally, JPMorgan Chase & Co. decreased their price objective on Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $274.81.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.